Orion Portfolio Solutions LLC Buys 186 Shares of Eli Lilly and Company (NYSE:LLY)

Orion Portfolio Solutions LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 3.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,570 shares of the company’s stock after purchasing an additional 186 shares during the period. Orion Portfolio Solutions LLC’s holdings in Eli Lilly and were worth $1,806,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of Eli Lilly and during the 4th quarter worth $2,213,765,000. Capital World Investors grew its holdings in shares of Eli Lilly and by 17.0% during the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after purchasing an additional 3,242,548 shares in the last quarter. Capital International Investors grew its holdings in shares of Eli Lilly and by 30.5% during the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after purchasing an additional 2,063,557 shares in the last quarter. 1832 Asset Management L.P. grew its holdings in shares of Eli Lilly and by 2,999.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,621,696 shares of the company’s stock worth $458,118,000 after purchasing an additional 1,569,368 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of Eli Lilly and by 38.5% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,525,748 shares of the company’s stock worth $1,254,743,000 after purchasing an additional 1,257,817 shares in the last quarter. Institutional investors own 82.45% of the company’s stock.

Eli Lilly and Stock Up 4.9 %

Shares of NYSE LLY opened at $310.87 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. The company’s fifty day simple moving average is $314.33 and its 200 day simple moving average is $304.45. Eli Lilly and Company has a 12-month low of $220.20 and a 12-month high of $335.33. The firm has a market cap of $295.38 billion, a PE ratio of 49.58, a P/E/G ratio of 1.92 and a beta of 0.38.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). The company had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the business posted $1.87 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Investors of record on Monday, August 15th were given a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.26%. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.

Insider Activity at Eli Lilly and

In other news, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the transaction, the insider now directly owns 103,875,441 shares of the company’s stock, valued at $34,574,940,536.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $332.85, for a total value of $29,776,095.30. Following the completion of the sale, the insider now directly owns 103,875,441 shares in the company, valued at $34,574,940,536.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the transaction, the senior vice president now owns 8,136 shares of the company’s stock, valued at $2,477,412. The disclosure for this sale can be found here. Insiders have sold a total of 328,125 shares of company stock valued at $108,581,151 over the last 90 days. 0.12% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. BMO Capital Markets upped their price objective on Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 6th. UBS Group upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $335.00 to $363.00 in a research report on Thursday. Morgan Stanley upped their price objective on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 7th. Citigroup upped their price objective on Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th. Finally, JPMorgan Chase & Co. increased their target price on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $332.19.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.